Swedish Orphan Biovitrum AB (publ) announces rights issue of approximately SEK 600 milllion
The board of directors of Swedish Orphan Biovitrum AB (publ) has resolved on a new share issue with preferential rights for the company’s shareholders of approximately SEK 600 million. The rights issue is subject to approval by the annual general meeting to be held on April 28, 2011.
Swedish Orphan Biovitrum is advised by Mannheimer Swartling in connection with the rights issue. The firm’s team is led by Nina Svensson and Isabella Ramsay, assisted primarily by Peter Grandelius, Rasmus Fahlén and Claudia Wallman. In addition, Daniel Karlsson and Catharina Belfrage Sahlstrand (financing) as well as Anne Rutberg and Carl Beyer (tax), among others, are involved in the rights issue.